• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Female Sexual Dysfunction - Pipeline Review, H2 2012 Product Image

Female Sexual Dysfunction - Pipeline Review, H2 2012

  • Published: September 2012
  • 77 pages
  • Global Markets Direct

Female Sexual Dysfunction – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Female Sexual Dysfunction - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Female Sexual Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Female Sexual Dysfunction. Female Sexual Dysfunction - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Female Sexual Dysfunction.
- A review of the Female Sexual Dysfunction products under READ MORE >

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Female Sexual Dysfunction Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Female Sexual Dysfunction 9
Female Sexual Dysfunction Therapeutics under Development by Companies 11
Female Sexual Dysfunction Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Female Sexual Dysfunction Therapeutics – Products under Development by Companies 18
Female Sexual Dysfunction Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Female Sexual Dysfunction Therapeutics Development 20
BioSante Pharmaceuticals, Inc. 20
Bayer AG 21
NexMed, Inc. 22
Palatin Technologies, Inc. 23
Urigen Pharmaceuticals, Inc. 24
M et P Pharma AG 25
Transtech Pharma, Inc. 26
Medisyn Technologies, Inc. 27
Lipocine Inc. 28
Female Sexual Dysfunction – Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
testosterone - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
testosterone - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
PL-6983 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
testosterone - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
bremelanotide - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
alprostadil - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
alprostadil - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
alprostadil - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
HPP-515 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Cyclophosphamide + Goserelin - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
testosterone - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
lepidium meyenii - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Lactate-Containing Vaginal Lubricant - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
MC4R Agonist - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
prasterone - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
testosterone - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Lybrido - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Female Sexual Dysfunction Therapeutics – Drug Profile Updates 59
Female Sexual Dysfunction Therapeutics – Discontinued Products 68
Female Sexual Dysfunction Therapeutics - Dormant Products 69
Female Sexual Dysfunction – Product Development Milestones 70
Featured News & Press Releases 70
Aug 16, 2012: Apricus Biosciences Announces Podium Presentation Of Femprox Phase III Clinical Data At 2012 World Meeting On Sexual Medicine 70
Jun 18, 2012: Trimel Hosts Investigator Meeting To Review Phase II Trial Of Tefina 70
Jun 15, 2012: Trimel Pharma Receives Approval To Conduct Tefina Clinical Study In Canada 71
Jun 11, 2012: BioSante Pharma Announces New LibiGel Phase III Efficacy Trials 71
May 21, 2012: Apricus Bio Announces Regulatory Meeting With FDA For Femprox For Treatment Of Female Sexual Arousal Disorder 72
May 17, 2012: Trimel's Tefina Phase II Clinical Trial Commences Enrollment 73
May 07, 2012: Apricus Obtains Pre-NDS Meeting For Femprox From Health Canada For Female Sexual Arousal Disorder 74
May 04, 2012: Apricus Bio Announces Poster Presentation Of Femprox Phase III Clinical Data At American Urological Association Annual Meeting 74
Apr 26, 2012: Shionogi Files NDA For Ospemifene Tablets For Treatment Of Vulvar And Vaginal Atrophy 75
Mar 21, 2012: Trimel Announces Positive Tefina Pharmacokinetic Study Results 75
Appendix 76
Methodology 76
Coverage 76
Secondary Research 76
Primary Research 76
Expert Panel Validation 76
Contact Us 77
Disclaimer 77

List of Tables
Number of Products Under Development for Female Sexual Dysfunction, H2 2012 9
Products under Development for Female Sexual Dysfunction – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
BioSante Pharmaceuticals, Inc., H2 2012 20
Bayer AG, H2 2012 21
NexMed, Inc., H2 2012 22
Palatin Technologies, Inc., H2 2012 23
Urigen Pharmaceuticals, Inc., H2 2012 24
M et P Pharma AG, H2 2012 25
Transtech Pharma, Inc., H2 2012 26
Medisyn Technologies, Inc., H2 2012 27
Lipocine Inc., H2 2012 28
Assessment by Monotherapy Products, H2 2012 29
Assessment by Combination Products, H2 2012 30
Assessment by Stage and Route of Administration, H2 2012 32
Assessment by Stage and Molecule Type, H2 2012 34
Female Sexual Dysfunction Therapeutics – Drug Profile Updates 59
Female Sexual Dysfunction Therapeutics – Discontinued Products 68
Female Sexual Dysfunction Therapeutics – Dormant Products 69

List of Figures
Number of Products under Development for Female Sexual Dysfunction, H2 2012 9
Products under Development for Female Sexual Dysfunction – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 13
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Discovery and Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 29
Assessment by Combination Products, H2 2012 30
Assessment by Route of Administration, H2 2012 31
Assessment by Stage and Route of Administration, H2 2012 32
Assessment by Molecule Type, H2 2012 33
Assessment by Stage and Molecule Type, H2 2012 34

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos